US-based biopharmaceutical firm CytomX Therapeutics has started dosing patients in a Phase I/II clinical trial (PROCLAIM CX-2009) of CX-2009 for the treatment of patients with select advanced solid tumours.
CX-2009 is a probody drug conjugate (PDC) being developed to target CD-166 antigen expressed in various types of tumours such as breast, endometrial and prostate cancers.
Go deeper with GlobalData
PDC targets the antigen particularly in the tumour microenvironment and delivers a tubulin-destabilising maytansine payload called DM4 to the cancer cells.
The dose-finding Phase I/II trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of CX-2009 as a monotherapy.
The trial will include subjects with several types of tumours such as non-small cell lung, breast, ovarian, endometrial, cholangiocarcinoma (bile duct cancer), head and neck and castration-resistant prostate cancers.
CytomX Therapeutics president and CEO Sean McCarthy said: "With CX-2009, we are leveraging the high levels of CD-166 on many types of cancer cells despite its presence on normal tissue.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"By targeting CD-166 and localising the activity of the CX-2009 probody therapeutic to the tumour, we could potentially treat a number of cancers for which few, if any, treatment options exist."
The Phase I/II trial is part of the firm’s international modular umbrella clinical trial programme called PROCLAIM designed for development of probody therapeutics.
In 2014, CytomX signed a licence agreement to develop PDCs using its antibody masking technology and tumour-selective protease substrates in conjunction with ImmunoGen’s potent antibody drug conjugate cell-killing agents and engineered linkers.
